alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 530.41 Drugs prohibited for extralabel use in animals. ( a ) The following drugs, families of drugs, and substances are prohibited for extralabel animal and human drug uses in food-producing animals. ( 1 ) Chloramphenicol;
( 2 ) Clenbuterol;
( 3 ) Diethylstilbestrol (DES);
( 4 ) Dimetridazole;
( 5 ) Ipronidazole;
( 6 ) Other nitroimidazoles;
( 7 ) Furazolidone.
( 8 ) Nitrofurazone.
( 9 ) Sulfonamide drugs in lactating dairy cattle (except approved use of sulfadimethoxine, sulfabromomethazine, and sulfaethoxypyridazine);
( 10 ) Fluoroquinolones; and
( 11 ) Glycopeptides.
( 12 ) Phenylbutazone in female dairy cattle 20 months of age or older.
( 13 ) Cephalosporins (not including cephapirin) in cattle, swine, chickens, or turkeys: ( i ) For disease prevention purposes;
( ii ) At unapproved doses, frequencies, durations, or routes of administration; or
( iii ) If the drug is not approved for that species and production class.
( b ) The following drugs, families of drugs, and substances are prohibited for extralabel animal and human drug uses in nonfood-producing animals: [Reserved]
( c ) [Reserved]
( d ) The following drugs, or classes of drugs, that are approved for treating or preventing influenza A, are prohibited from extralabel use in chickens, turkeys, and ducks: ( 1 ) Adamantanes.
( 2 ) Neuraminidase inhibitors.
[62 FR 27947, May 22, 1997, as amended at 67 FR 5471, Feb. 6, 2002; 68 FR 9530, Feb. 28, 2003; 68 FR 14134, Mar. 24, 2003; 71 FR 14377, Mar. 22, 2006; 77 FR 745, Jan. 6, 2012]
<PAGE>   1

                                4,500,000 Shares

                                   N2H2, Inc.

                                  Common Stock

                         FORM OF UNDERWRITING AGREEMENT


                                                                   July __, 1999


CIBC World Markets Corp.
U.S. Bancorp Piper Jaffray, Inc.
c/o     CIBC World Markets Corp.
        One World Financial Center
        New York, New York  10281

On behalf of the Several
Underwriters named on
Schedule I attached hereto.

Ladies and Gentlemen:

        N2H2, Inc., a Washington corporation (the "Company"), and the
shareholders of the Company named in Schedule II to this Agreement (the "Selling
Shareholders," which term shall include, except where otherwise noted, that
certain shareholder of the Company named as the "Affiliated Selling Shareholder"
in Schedule II hereto) severally propose, subject to the terms and conditions
contained herein, to sell to you and the other underwriters named on Schedule I
to this Agreement (the "Underwriters"), for whom you are acting as
Representatives (the "Representatives"), an aggregate of 4,500,000 shares (the
"Firm Shares") of the Company's Common Stock, no par value (the "Common Stock").
Of the Firm Shares, 4,450,000 are to be issued and sold by the Company and
50,000 are to be sold by the Selling Shareholders. The respective amounts of the
Firm Shares to be purchased by each of the several Underwriters are set forth
opposite their names on Schedule I hereto. In addition, the Company proposes to
grant to the Underwriters an option to purchase up to an additional 675,000
shares (the "Option Shares") of Common Stock from it for the purpose of covering
over-allotments in connection with the sale of the Firm Shares. The Firm Shares
and the Option Shares are together called the "Shares."

        1. SALE AND PURCHASE OF THE SHARES.

        On the basis of the representations, warranties and agreements contained
in, and subject to the terms and conditions of, this Agreement:

               (a) The Company agrees to issue and sell to each of the
Underwriters, and each of the Underwriters agrees, severally and not jointly, to
purchase from the Company, at a price of $_____ per share (the "Initial Price"),
the number of Firm Shares set forth opposite the name of such Underwriter under
the column "Number of Firm Shares to be Purchased from the


                                       1.
§ 501.17 Animal food labeling warning statements. ( a ) *Self-pressurized containers.* ( 1 ) The label of a food packaged in a self-pressurized container and intended to be expelled from the package under pressure shall bear the following warning: *Warning* Avoid spraying in eyes. Contents under pressure. Do not puncture or incinerate. Do not store at temperature above 120 °F. Keep out of reach of children.
( 2 ) In the case of products intended for use by children, the phrase “except under adult supervision” may be added at the end of the last sentence in the warning required by paragraph (a)(1) of this section.
( 3 ) In the case of products packaged in glass containers, the word “break” may be substituted for the word “puncture” in the warning required by paragraph (a)(1) of this section.
( 4 ) The words “Avoid spraying in eyes” may be deleted from the warning required by paragraph (a)(1) of this section in the case of a product not expelled as a spray.
( b ) *Self-pressurized containers with halocarbon or hydrocarbon propellants.* ( 1 ) In addition to the warning required by paragraph (a) of this section, the label of a food packaged in a self-pressurized container in which the propellant consists in whole or in part of a halocarbon or a hydrocarbon shall bear the following warning: *Warning* Use only as directed. Intentional misuse by deliberately concentrating and inhaling the contents can be harmful or fatal.
( 2 ) The warning required by paragraph (b)(1) of this section is not required for the following products: ( i ) Products expelled in the form of a foam or cream, which contain less than 10 percent propellant in the container.
( ii ) Products in a container with a physical barrier that prevents escape of the propellant at the time of use.
( iii ) Products of a net quantity of contents of less than 2 ozs that are designed to release a measured amount of product with each valve actuation.
( iv ) Products of a net quantity of contents of less than 1 ⁄ 2 oz.
( c ) *Animal food containing or manufactured with a chlorofluorocarbon or other ozone-depleting substance.* Labeling requirements for animal foods that contain or are manufactured with a chlorofluorocarbon or other ozone-depleting substance designated by the Environmental Protection Agency (EPA) are set forth in 40 CFR part 82.
[41 FR 38619, Sept. 10, 1976, as amended at 42 FR 22033, Apr. 29, 1977; 61 FR 20101, May 3, 1996]
§ 640.104 Potency. ( a ) *Antibody levels and tests.* Each lot of final product shall contain at least the minimum levels of antibodies for diphtheria, measles, and for at least one type of poliomyelitis. In the event the final bulk solution is stored at a temperature above 5 °C the antibody level tests shall be performed after such storage with a sample of the stored material.
( b ) *Minimum levels.* The minimum antibody levels are as follows: ( 1 ) No less than 2 units of diphtheria antitoxin per ml.
( 2 ) A measles neutralizing antibody level that, when compared with that of a reference material designated by the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, as indicated in paragraph (c) of this section, demonstrates adequate potency. The Director, CBER, shall notify manufacturers when a new reference material will be used and will advise manufacturers of an appropriate antibody level taking into account a comparison of the new reference material to the previous reference material.
( 3 ) A poliomyelitis Type 1, Type 2, or Type 3 neutralizing antibody level that, when compared with that of a reference material designated by the Center for Biologics Evaluation and Research, Food and Drug Administration, as indicated in paragraph (c) of this section, demonstrates adequate potency. The Director, CBER, shall notify manufacturers when a new reference material will be used and will advise manufacturers of an appropriate antibody level taking into account a comparison of the new reference material to the previous reference material.
( c ) *Reference materials.* The following reference materials shall be obtained from the Center for Biologics Evaluation and Research: ( 1 ) Reference Immune Globulin for correlation of measles antibody titers.
( 2 ) Reference Immune Globulin for correlation of poliomyelitis antibody titers, Types 1, 2, and 3.
[38 FR 32089, Nov. 20, 1973, as amended at 39 FR 9661, Mar. 13, 1974; 49 FR 23834, June 8, 1984; 50 FR 4140, Jan. 29, 1985; 55 FR 11013, Mar. 26, 1990; 63 FR 16685, Apr. 6, 1998; 64 FR 26287, May 14, 1999]
#### § 600.22 [Reserved]
§ 58.206 Final order on disqualification. ( a ) If the Commissioner, after the regulatory hearing, or after the time for requesting a hearing expires without a request being made, upon an evaluation of the administrative record of the disqualification proceeding, makes the findings required in § 58.202, he shall issue a final order disqualifying the facility. Such order shall include a statement of the basis for that determination. Upon issuing a final order, the Commissioner shall notify (with a copy of the order) the testing facility of the action.
( b ) If the Commissioner, after a regulatory hearing or after the time for requesting a hearing expires without a request being made, upon an evaluation of the administrative record of the disqualification proceeding, does not make the findings required in § 58.202, he shall issue a final order terminating the disqualification proceeding. Such order shall include a statement of the basis for that determination. Upon issuing a final order the Commissioner shall notify the testing facility and provide a copy of the order.
#### William Herbert et al. *v.*Frederick Smyth et al.

King, C. J., Alcorn, House, Cotter and Ryan, Js.

Argued May 13

decided May 21, 1969

*Walter M. Pickett, Jr.,*for the appellants (defendants).

*Robert J. Sullivan,*for the appellees (plaintiffs).

Per Curiam.

The trial court followed the rescript as set forth in *Herbert*v. *Smyth,*155 Conn. 78, 86, 230 A.2d 235.

There is no error.
<PAGE>
 
                                  Exhibit 21
                        Subsidiaries of the Registrant


Subsidiaries of The Guarantee Life Companies Inc. as of December 31, 1998
-------------------------------------------------------------------------

 .   Guarantee Life Insurance Company, a Nebraska stock insurance company
 .   Guarantee Protective Life Company, a Nebraska stock insurance company
 .   Westfield Life Insurance Company, a Nebraska stock insurance company
 .   PFG, Inc., a Pennsylvania corporation (of which The Guarantee Life Companies
    Inc. owns 75% of the voting stock and Guarantee Life Insurance Company owns
    25% of the voting stock)

         Subsidiaries of PFG, Inc.:

         .   Philadelphia Financial Group, Inc., a Delaware corporation;
         .   PFG Distribution Co., a Delaware corporation; and
         .   AGL Life Assurance Company, a Pennsylvania corporation
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7643 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7643

    To amend title 38, United States Code, to authorize the use of 
   Department of Veterans Affairs work-study allowance to carry out 
casework, policy making, and oversight related to the activities of the 
              Department at certain congressional offices.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 12, 2024

  Mr. Takano introduced the following bill; which was referred to the 
                     Committee on Veterans' Affairs

_______________________________________________________________________

                                 A BILL

 
    To amend title 38, United States Code, to authorize the use of 
   Department of Veterans Affairs work-study allowance to carry out 
casework, policy making, and oversight related to the activities of the 
              Department at certain congressional offices.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Veterans Congressional Work Study 
Act of 2024''.

SEC. 2. AUTHORIZED ACTIVITIES IN CERTAIN CONGRESSIONAL OFFICES USING 
              DEPARTMENT OF VETERANS AFFAIRS WORK-STUDY ALLOWANCE.

    Section 3485(a)(5) of title 38, United States Code, is amended--
            (1) in subparagraph (K), by inserting ``or at the offices 
        of a committee of the Senate or House of Representatives on 
        behalf of such committee'' after ``such Members''; and
            (2) by adding at the end the following new subparagraph:
            ``(L) Activities supporting casework, policy making, and 
        oversight related to the activities of the Department carried 
        out at the offices of a committee of the Senate or House of 
        Representatives, the Congressional Research Service, the 
        Government Accountability Office, or the Congressional Budget 
        Office.''.
                                 <all>
```
##### 



Exhibit 18.1 February 28, 2005 The Audit Committee
Independence Community Bank Corp.
195 Montague Street
Brooklyn, New York 11201 Note 15 of the Notes to the Consolidated Financial Statements of Independence Community Bank Corp.
(the Company) included in its Annual Report on Form 10-K for the year ended December 31, 2004
describes a change in the measurement date for its pension and postretirement plans from January 1
to December 1. Management believes that the change in measurement date is preferable in the
circumstances because it (i) improves the Companys control procedures by allowing additional time
for management to review the completeness and accuracy of the actuarial pension and postretirement
measurements and (ii) allows the Company to fully address this matter before the Companys staff is
immersed in the process of preparing the Companys year-end financial statements and the conclusion
of the initial evaluation of internal controls over financial reporting. The Company has stated
that the new measurement date will also allow the Company adequate time to review its pension and
postretirement plans calculations prior to future Securities and Exchange Commission accelerated
filing requirements. In accordance with your request, we have reviewed and discussed with the Companys management the
circumstances and business judgment and planning upon which the decision to make this change in the
method of accounting was based. With regard to the aforementioned accounting change, authoritative
criteria have not been established for evaluating the preferability of one acceptable method of
accounting over another acceptable method. However, based on our review and discussion with and
reliance on managements business judgment, we concur that the change in measurement date is
preferable in the Companys circumstances. Very truly yours, Ernst & Young
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7418 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7418

To amend the Internal Revenue Code of 1986 to exclude from gross income 
          certain compensation to clinical trial participants.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 20, 2024

Mr. Kelly of Pennsylvania (for himself and Ms. Houlahan) introduced the 
 following bill; which was referred to the Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
To amend the Internal Revenue Code of 1986 to exclude from gross income 
          certain compensation to clinical trial participants.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. EXCLUSION OF COMPENSATION PROVIDED TO PARTICIPANTS IN 
              CLINICAL TRIALS.

    (a) In General.--Part III of subchapter B of chapter 1 of the 
Internal Revenue Code of 1986 is amended by inserting after section 
139I the following new section:

``SEC. 139J. CLINICAL TRIAL PAYMENTS.

    ``(a) In General.--Gross income shall not include any amount 
received by an individual as a qualified clinical trial payment.
    ``(b) Qualified Clinical Trial Payment Defined.--For purposes of 
this section, the term `qualified clinical trial payment' means any 
amount paid to an individual--
            ``(1) as compensation for participation by the individual 
        or a dependent of the individual in an approved clinical trial, 
        or
            ``(2) to reimburse or pay reasonable and necessary expenses 
        incurred in connection with participation by the individual or 
        a dependent of the individual in an approved clinical trial.
    ``(c) Other Definitions.--For purposes of this section--
            ``(1) Approved clinical trial.--The term `approved clinical 
        trial' has the meaning given such term in section 2709(d)(1) of 
        the Public Health Service Act (42 U.S.C. 300gg-8(d)(1)), 
        determined by applying `disease or condition' for `life-
        threatening disease or condition'.
            ``(2) Dependent.--The term `dependent' has the meaning 
        given such term in section 152.''.
    (b) Clerical Amendment.--The table of sections for part III of 
subchapter B of chapter 1 of such Code is amended by inserting after 
the item relating to section 139I the following new item:

``Sec. 139J. Clinical trial payments.''.
    (c) Effective Date.--The amendment made by this section shall apply 
to amounts paid after December 31, 2023.
                                 <all>
```
Court of Appeals

of the State of Georgia

ATLANTA,____________________

The Court of Appeals hereby passes the following order:

A19A1925. SEBORIS ROBINSON BROOKS, JR. v. THE STATE.

Seboris Robinson Brooks, Jr., was convicted of murder and other offenses and

was sentenced to life in prison. The Supreme Court affirmed his convictions on direct

appeal. See Brooks v. State, 281 Ga. 14 (635 SE2d 723) (2006). Brooks subsequently

challenged his convictions by filing a “motion to set aside a void indictment,” which

the trial court denied. Brooks then appealed to this Court. 

Under our Constitution, however, the Supreme Court has appellate jurisdiction

over “[a]ll cases in which a sentence of death was imposed or could be imposed.” See

Ga. Const. of 1983, Art. VI, Sec. VI, Par. III (8). Because a penalty of death can be

imposed for the crime of murder, jurisdiction is proper in the Supreme Court. See

OCGA § 17-10-30 (b); Neal v. State, 290 Ga. 563, 572 (722 SE2d 765) (2012)

(Hunstein, C. J., concurring); see also State v. Thornton, 253 Ga. 524, 524 (1) (322

SE2d 711) (1984) (directing this Court to transfer “all casesin which either a sentence

of death or of life imprisonment has been imposed upon conviction of murder”). The

Supreme Court’sjurisdiction overmurder cases includes appealsfromordersresolving

post-judgment motions in such cases. See Simpson v. State, 292 Ga. 764 (740 SE2d

124) (2013) (appeal from denial of motion attacking murder convictions as void).

Accordingly, this appeal is hereby TRANSFERRED to the Supreme Court for

disposition.

Court of Appeals of the State of Georgia

Clerk’s Office, Atlanta,____________________

I certify that the above is a true extract from

the minutes of the Court of Appeals of Georgia.

Witness my signature and the seal of said court

hereto affixed the day and year last above written.

, Clerk.

June 19, 2019

06/19/2019
================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   ----------

                                    FORM 8-K

                CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                           THE SECURITIES ACT OF 1934

                                   May 8, 2003

                        Commission File Number 000-21755

                                   ----------

                                iGATE CORPORATION
             (Exact name of registrant as specified in its charter)

           PENNSYLVANIA                                          25-1802235
  (State or other jurisdiction                                (I.R.S. Employer
of incorporation or organization)                            Identification No.)

  1000 Commerce Drive
  Suite 500
  Pittsburgh, PA                                                   15275
  (Address of Principal Offices)                                 (Zip Code)

                                 (412) 503-1131
              (Registrant's Telephone Number, Including Area Code)

================================================================================

<PAGE>

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

99.1 Press Release issued by iGate Corporation on May 8, 2003.

Item 9. Regulation FD Disclosure.

The following information is intended to be included under "Item 12. Results of
Operations and Financial Condition" and is included under this Item 9 in
accordance with SEC Release No. 33-8216.

On May 8, 2003, iGate Corporation reported its earnings for the quarter ended
March 31, 2003. Attached to this Current Report on Form 8-K as Exhibit 99.1 is a
copy of the Corporation's related press release dated May 8, 2003 which is
incorporated herein.

The information in this report is being furnished, not filed. Accordingly, the
information in Item 9 of this report will not be incorporated by reference into
any registration statement filed by the Corporation under the Securities Act of
1933, as amended, unless specifically identified therein as being incorporated
by reference.

<PAGE>

                                   SIGNATURES

      Pursuant to the requirements of the Securities and Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                  iGATE CORPORATION

May 8, 2003                       /s/ MICHAEL ZUGAY
                                  Michael Zugay
                                  Senior Vice President, Chief Financial Officer

                                  EXHIBIT INDEX

(c) Exhibits

      Exhibit No.

         99.1      Press Release dated May 8, 2003.
#### § 358.603 Definition.

As used in this subpart:

*Pediculicide drug product.* A drug product for the treatment of head, pubic (crab), and body lice.
EXHIBIT 32.1









CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO


18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002








This certification is provided pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and accompanies the Quarterly Report on Form 10-Q (the “Form 10-Q”) for the quarter ended September 30, 2010 of Crimson Exploration Inc. (the “Issuer”).  The undersigned hereby certifies that the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Issuer.





Date:
November 10, 2010/s/ Allan D. KeelName:
Allan D. KeelTitle:
President and Chief Executive Officer








A signed original of this written statement required by Section 906 has been provided to the Issuer and will be furnished to the Securities and Exchange Commission, or its staff, upon request.